Aberdeen Group plc lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 1,131.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 92,508 shares of the company's stock after purchasing an additional 84,998 shares during the period. Aberdeen Group plc owned 0.12% of IDEXX Laboratories worth $48,307,000 at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in IDXX. Arlington Trust Co LLC increased its position in shares of IDEXX Laboratories by 46.3% in the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company's stock valued at $32,000 after buying an additional 19 shares in the last quarter. Bell Investment Advisors Inc raised its stake in IDEXX Laboratories by 45.5% during the 3rd quarter. Bell Investment Advisors Inc now owns 64 shares of the company's stock worth $33,000 after buying an additional 20 shares during the period. Annis Gardner Whiting Capital Advisors LLC lifted its holdings in IDEXX Laboratories by 21.4% during the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 119 shares of the company's stock worth $67,000 after acquiring an additional 21 shares in the last quarter. Valeo Financial Advisors LLC lifted its holdings in IDEXX Laboratories by 6.4% during the second quarter. Valeo Financial Advisors LLC now owns 383 shares of the company's stock worth $202,000 after acquiring an additional 23 shares in the last quarter. Finally, Meeder Advisory Services Inc. lifted its holdings in IDEXX Laboratories by 1.3% during the first quarter. Meeder Advisory Services Inc. now owns 1,896 shares of the company's stock worth $1,066,000 after acquiring an additional 25 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at IDEXX Laboratories
In related news, Director Daniel Junius sold 1,200 shares of the stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $704.07, for a total transaction of $844,884.00. Following the completion of the transaction, the director directly owned 2,361 shares of the company's stock, valued at approximately $1,662,309.27. This represents a 33.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Sharon Underberg sold 8,906 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $688.59, for a total value of $6,132,582.54. Following the transaction, the executive vice president directly owned 7,169 shares of the company's stock, valued at $4,936,501.71. This trade represents a 55.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 41,428 shares of company stock valued at $28,567,934 in the last ninety days. Insiders own 0.79% of the company's stock.
IDEXX Laboratories Price Performance
Shares of IDXX stock opened at $704.23 on Monday. The company has a current ratio of 1.19, a quick ratio of 0.88 and a debt-to-equity ratio of 0.16. IDEXX Laboratories, Inc. has a 1 year low of $500.61 and a 1 year high of $769.98. The firm's fifty day moving average price is $562.41 and its two-hundred day moving average price is $573.52. The firm has a market capitalization of $55.49 billion, a P/E ratio of 47.49 and a beta of 1.55.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported $3.96 EPS for the quarter, topping the consensus estimate of $3.71 by $0.25. The firm had revenue of $1.21 billion for the quarter, compared to analysts' expectations of $1.19 billion. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. The company's revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the previous year, the firm posted $3.22 EPS. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 15.05 EPS for the current fiscal year.
Analyst Ratings Changes
A number of research firms have recently commented on IDXX. UBS Group raised their price target on IDEXX Laboratories from $627.00 to $700.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 3rd. The Goldman Sachs Group initiated coverage on IDEXX Laboratories in a research report on Friday, October 16th. They issued a "buy" rating and a $740.00 price objective for the company. Citigroup increased their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 5th. JPMorgan Chase & Co. dropped their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set an "overweight" rating on the stock in a report on Friday, October 16th. Finally, Weiss Ratings raised shares of IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, October 8th. Seven equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $717.27.
View Our Latest Research Report on IDEXX Laboratories
IDEXX Laboratories Profile
(
Free Report)
IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.